Lapatinib-d4

• UNSPSC Description:

  Lapatinib-d4 is the deuterium labeled Lapatinib (HY-50898). Lapatinib is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1][2].

• Target Antigen:

  Autophagy; EGFR; Ferroptosis

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Apoptosis;Autophagy;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.02

• Solubility:

  10 mM in DMSO

• Smiles:

  CS(C([2H])([2H])C([2H])([2H])NCC1=CC=C(O1)C2=CC(C(NC3=CC(Cl)=C(C=C3)OCC4=CC(F)=CC=C4)=NC=N5)=C5C=C2)(=O)=O

• Molecular Weight:

  585.08

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1(2):85-94.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1184263-99-7